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PDrug-Eluting Compared With Bare-Metal
Coronary Stents Among Elderly Patients
Peter W. Groeneveld, MD, MS,*†‡ Mary Anne Matta, MS,† Alexis P. Greenhut, MPH,†
Feifei Yang, MS†
Philadelphia, Pennsylvania
Objectives We sought to determine whether drug-eluting stents (DES) were associated with improved clinical outcomes com-
pared with bare-metal stents (BMS) among a nationally representative, nonexperimental elderly patient cohort.
Background Randomized controlled clinical trials comparing DES and BMS for treatment of coronary artery disease indicate
that although the use of DES reduces rates of coronary restenosis after percutaneous coronary intervention, it
does not reduce the rates of mortality or acute myocardial infarction (AMI). Nevertheless, clinical outcomes of
DES in nonexperimental, routine clinical practice are uncertain.
Methods We assembled a retrospective cohort of elderly Medicare beneficiaries (n  76,525) who received DES within 9
months after Food and Drug Administration approval of the sirolimus-eluting stent (April 2003 to December
2003). Using propensity score methods, we assembled 2 matched control cohorts who received BMS from July
2002 to March 2003 (historical controls) or from April 2003 to December 2003 (contemporary controls). Patient
enrollment and claims records were obtained through December 2005 to ascertain mortality, hospitalization for
AMI, and subsequent coronary revascularization.
Results Receipt of a DES was associated with a significant survival benefit, with an adjusted mortality hazard ratio of
0.83 (95% confidence interval 0.81 to 0.86) compared with contemporary controls, and a hazard ratio of 0.79
(95% confidence interval 0.77 to 0.81) compared with historical controls (control group heterogeneity: p 
0.001). Patients with DES had significantly lower adjusted rates of revascularization procedures within the first
2 years after PCI and lower hospitalization rates for subsequent AMI.
Conclusions In contrast to clinical trial results, DES receipt was associated with fewer subsequent revascularization procedures,
lower rates of hospitalization for AMI, and improved survival among elderly Medicare beneficiaries. (J Am Coll
Cardiol 2008;51:2017–24) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.01.057i
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che first drug-eluting (coronary) stents (DES) used in
outine clinical practice in the U.S.—sirolimus-eluting
tents—received initial Food and Drug Administration
FDA) approval in April 2003 (1). Adoption of this new
echnology, augmented by the approval of the paclitaxel-
luting stent in March 2004, was rapid and widespread,
uch that the majority of percutaneous coronary interven-
ion (PCI) procedures in the U.S. now use 1 of the 2
DA-approved DES (2,3), and the annual market for DES
rom the *Department of Veterans Affairs Center for Health Equity Research and
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upported by a Research Career Development Award from the Department of Veterans
ffairs’ Health Services Research and Development Service, Washington, DC.h
Manuscript received November 16, 2007; revised manuscript received January 4,
008, accepted January 8, 2008.n the U.S. alone has reached $5.3 billion (4). Despite the
apid diffusion and widespread acceptance of this new
echnology, the clinical effectiveness of DES compared with
he less-expensive bare-metal (coronary) stents (BMS) re-
ains uncertain, particularly when coronary stents are used
n routine, nonexperimental clinical settings.
See page 2025
The authors of numerous randomized controlled clinical
rials have consistently demonstrated that the use of DES
educes the rate of target lesion revascularization (i.e., the
eed to perform a repeat interventional procedure on a
oronary stenosis that had recurred at the site of the initial
tenting) compared with BMS, but DES do not reduce
ubsequent rates of major adverse clinical events or mortality
5–7). More recently, reports from clinical registries and
linical trial consortiums with longer-term follow-up data
ave suggested the possibility of a higher rate of late
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DES Outcomes in the Elderly May 27, 2008:2017–24stent failures—in particular, stent
thrombosis—for patients receiving
DES, which might further dimin-
ish the relative benefit of DES
(8–10). Extrapolating clinical trial
results to nonexperimental settings
has been further complicated by
the diverse clinical indications for
which DES are currently used. It
has been estimated that approxi-
mately 60% of drug-eluting stent
use in the U.S. has been “off label,”
hat is, used in patients with clinical conditions that do not
recisely fit the FDA-approved clinical criteria that was based
n entry criteria for the clinical trials (11). It is therefore
ncertain whether the clinical outcomes observed in experi-
ental settings for DES are representative of those obtained in
outine clinical practice. Therefore, the goals of this research
ere to measure the clinical outcomes of DES compared with
MS among a nationally representative cohort of elderly
atients receiving PCI in nonexperimental settings.
ethods
etting. The population for the study comprised Medicare
eneficiaries ages 66 and older covered under fee-for-service
edicare. Medicare Part A (hospital) coverage is almost
niversal for Americans older than the age of 65 years, and
ore than 90% of elderly Americans are enrolled in fee-
or-service Medicare; thus, this population is nearly ideal for
nvestigations of national trends in health care. From among
hese Medicare beneficiaries (i.e., approximately 45 million
ersons), we identified patients with hospital claims indi-
ating receipt of a DES between April 24, 2003 (the FDA
pproval date for DES), through December 2003, or receipt
f a BMS from July 1, 2002, through December 31, 2003.
Patients with procedure codes indicating receipt of both
tent types during the same hospitalization were excluded.
e also excluded any patients who had prior Medicare
laims indicating they had undergone PCI or coronary
ypass surgery within the 6-month period before the “index”
CI that qualified the patient for inclusion in our study.
atients were only allowed to enter the cohort once—at
heir earliest PCI within the designated time windows. We
nly included patients ages 66 years and older, because
any 65-year-old patients would not be expected to have
ad at least 6 months of previous Medicare coverage during
hich time information on prior procedures and comorbidi-
ies would have been recorded.
omparison groups. For all qualifying DES and BMS
ecipients, we obtained data on age, race, and gender from
he Medicare enrollment database. Information on clinical
omorbidities and other cardiac diagnoses (e.g., acute myo-
ardial infarction or acute coronary syndromes) was ob-
Abbreviations
and Acronyms
AMI  acute myocardial
infarction
BMS  bare-metal stent(s)
DES  drug-eluting stent(s)
FDA  Food and Drug
Administration
PCI  percutaneous
coronary interventionained from the hospitalization claim at the time of PCI wi.e., the index admission), as well as all other inpatient
laims during the 6 months before the index hospitalization.
e also determined whether each patient’s index hospital-
zation had been classified as elective, urgent, or emergent.
nformation on the patient’s PCI hospital, including geo-
raphic location and academic status (indicated by mem-
ership in the American Association of Medical College’s
ouncil of Teaching Hospitals and Health Systems), was
btained by linking each patient’s hospital identifier to
nnual Hospital Cost Report Information System report
ata that are submitted annually to the Centers for Medi-
are and Medicaid Services by all hospitals participating in
he Medicare program. The volume of Medicare admissions
er calendar year for each admitting hospital was calculated
sing all Medicare acute-care hospitalization claims from
002 to 2004.
All DES and BMS recipients were then combined in a
ingle dataset, and a multivariate propensity score for receipt
f DES was calculated for each patient using a multivariable
ogistic regression model with receipt of DES (vs. BMS)
eing the dependent variable, and the demographic, clinical,
nd hospital factors listed previously included in the model
s independent variables (12). The propensity score is a
ell-validated statistical method designed to balance a large
umber of potential confounders equally across 2 observa-
ional cohorts of patients, without the traditional require-
ent of exactly matching patients 1-to-1 on each individual
onfounder (12,13).
We then matched each DES recipient to a BMS control
atient by using a propensity score-matching optimization
lgorithm that selected an optimal match for each DES
ecipient among BMS patients with similar propensity
cores (within 0.25 times the standard deviation of the
ropensity score logit) and having a minimum Mahalanobis
istance calculated from key covariates (in this case, the
ovariates were age, diabetes, congestive heart failure, acute
yocardial infarction, PCI at a high-volume center, and
CI at an academic center) (13). Because the pool of
otential BMS controls receiving stents in the time period
efore FDA approval of the DES (April 2003), may have
ystematically differed in unobservable ways from the pool
f potential BMS controls available after the FDA approval
ate, we matched DES patients separately to “contempo-
ary” BMS controls, that is, BMS patients receiving stents
uring the same time interval (April to December, 2003)
uring which the DES patients received stents, as well as to
historical” controls, that is, BMS patients receiving stents
uring the 9 months immediately before the FDA approval
f DES (July 2002 to March 2003). All subsequent analyses
f clinical outcomes were made in parallel between these 2
airs of matched DES-BMS cohorts.
scertaining clinical outcomes. Using the Medicare De-
ominator File, which is linked to the Social Security
dministration’s Death Master File and thus is a reliable
ndicator of mortality (14), we determined whether and
hen patients had died during the time interval from receipt
o
i
d
d
d
s
l
S
p
s
T
t
d
s
a
u
w
m
r
f
a
c
t
m
i
p
a
t
p
l
p
b
p
l
R
A
p
2
m
p
w
d
o
o
p
p
a
e
o
g
c
B
d
A
fi
t
y
h
h
t
t
p
a
M
o
a
c
c
m
m
f
S
d
b
m
r
a
p
s
a
d
r
p
0
c
(
h
s
t
d
t
c
b
v
a
l
p
c
o
d
d
m
S
e
r
d
d
w
2019JACC Vol. 51, No. 21, 2008 Groeneveld et al.
May 27, 2008:2017–24 DES Outcomes in the Elderlyf PCI through December 31, 2005, the last available date
n our database. We used inpatient claims in the Medicare
atabase subsequent to the index stent receipt date to
etermine whether patients had been hospitalized with a
iagnosis of acute myocardial infarction after receiving their
tent and/or if they underwent additional coronary revascu-
arization procedures after the initial PCI.
tatistical analyses. Standardized differences, calculated as
ercentages, were used to assess the quality of the propensity
core match in reducing the potential for selection bias (13).
he percent standardized difference is calculated by dividing
he absolute difference in means by the pooled standard
eviation. Standardized differences of 5% after a propen-
ity score match are generally considered indicative of
dequate matching on a particular variable (15).
Chi-square tests were used to compare differences in
nadjusted outcomes ratios for DES recipients compared
ith BMS recipients. Cox proportional hazards survival
odels were fitted to compare mortality rates. Logistic
egression was used to compare the odds of hospitalization
or acute myocardial infarction, coronary revascularization,
nd the combined end point of mortality, coronary revas-
ularization, or hospitalization for acute myocardial infarc-
ion at 1 and 2 years after PCI. The initial (unadjusted)
odels included only receipt of DES versus BMS as an
ndependent variable. To further ascertain whether the
ropensity score match had successfully balanced covariates,
s well as to control for residual confounding, we then fit
hese models with additional covariates, including the pro-
ensity score as well as all demographic, clinical, or hospital-
evel variables that were potentially not well-balanced (i.e.,
 0.1 for comparison of means) across subcohorts defined
y quintiles of propensity scores. All data analyses were
erformed with SAS 9.1 (SAS Institute, Cary, North Caro-
ina). A p value of 0.05 was considered statistically significant.
esults
nalytic cohorts: match quality. We identified 76,525
atients who received DES from April through December
003. Of these patients, 71,965 (94%) were able to be
atched to contemporary BMS controls, and all DES
atients were able to be matched to historical BMS controls
ith the use of propensity score matching. There were
ifferences in the age, race, geographic location, prevalence
f selected cardiovascular diseases, and the prevalence of
ther clinical comorbidities between DES patients and all
otential historical BMS controls (Table 1) as well as all
otential contemporary BMS controls (Table 2). However,
fter implementation of the propensity score match and
xclusion of unmatchable patients, subsequent comparisons
f standardized differences in propensity scores, demo-
raphics, geographic factors, hospital factors, and clinical
haracteristics between propensity-score-matched DES and
MS cohorts revealed minimal residual differences in the
istribution of covariates. pnalytic cohorts: descriptive statistics. Patients in the
nal (matched) analytic cohorts were predominantly white,
he majority of patients were men, and the mean age was 75
ears. Approximately 14% to 15% of patients had congestive
eart failure, and approximately one-quarter of the patients
ad been hospitalized with acute myocardial infarction at
he time of their coronary stent implantation. Slightly less
han one-third of each cohort had diabetes. The majority of
atients were admitted to high-volume (10,000 Medicare
dmissions per year) or moderate-volume (5,000 to 10,000
edicare admissions per year) hospitals. Approximately
ne-half of each cohort was admitted to hospitals in urban
reas, and approximately one-quarter of each cohort re-
eived PCI in academic hospitals. Patients in the DES
ohort were followed for a mean of 2.3 years. Patients in the
atched contemporary BMS cohort were followed for a
ean of 2.4 years, whereas historical BMS controls were
ollowed for a mean of 3.1 years.
urvival. Recipients of DES had significantly lower 90-
ay, 1-year, and 2-year unadjusted mortality compared with
oth matched contemporary BMS controls as well as
atched historical BMS controls (Table 3). The absolute
eduction in mortality at 2 years for DES patients was
pproximately 2% for the comparisons with both contem-
orary and historical controls. In Cox proportional hazards
urvival models that adjusted for the propensity score as well
s for covariates that had residual, statistically significant
ifferences across quintiles of propensity scores, DES receipt
emained a significant predictor of improved survival com-
ared with BMS receipt, with an adjusted hazard ratio of
.83 (95% confidence interval 0.81 to 0.86) compared with
ontemporary controls, and an adjusted hazard ratio of 0.79
95% confidence interval 0.77 to 0.81) compared with
istorical controls (Table 4). The 2 control groups were
ignificantly heterogeneous (p  0.001). Comparisons be-
ween unadjusted and adjusted coefficients and their confi-
ence intervals indicated minimal differences, suggesting
he propensity match had effectively balanced observed
onfounders. As a sensitivity analysis, we calculated “Rosen-
aum bounds” for the minimum effect size of an unobserved
ariable necessary to confound the association between DES
nd survival (16). These calculations indicated the preva-
ence of such a factor must differ between DES and BMS
atients by a minimum of a 16% standardized difference. By
omparison, among the 25 observed variables included in
ur propensity match, only the prevalence of acute myocar-
ial infarction differed by more than a 16% standardized
ifference between DES and BMS patients before
atching.
ubsequent coronary revascularization procedures. Drug-
luting stent patients had lower rates of additional coronary
evascularization procedures such as additional PCI proce-
ures or subsequent coronary bypass surgery. Absolute
ifferences in revascularization rates were approximately 2%
hen compared with contemporary controls and 3% com-
ared with historical controls, within the first year, with the
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DES Outcomes in the Elderly May 27, 2008:2017–24ame absolute differences maintained in the second year. In
ultivariate analyses DES recipients had significantly lower
djusted odds of undergoing additional coronary procedures
ompared with both contemporary and historical BMS
ontrols.
ajor adverse clinical events. Patients who received DES
ad lower unadjusted hospitalization rates for acute myo-
ardial infarction, with absolute differences ranging from 2%
o 2.5%. Adjusted rates of hospitalization for subsequent
cute myocardial infarction were likewise lower for DES
atients compared with both contemporary and historical
atients Receiving DES Compared With Historical BMS Controls*
Table 1 Patients Receiving DES Compared With Historical BMS
Characteristic
Before Match
DES
(n  76,525)
BMS
(n  164,140)
Logit of propensity score (SD) 0.81 (0.27) 0.88 (0.27)
Age, yrs, mean (SD) 75 (6) 75 (6)
Female 33,299 (44) 70,902 (43)
Race
White 70,241 (92) 150,405 (92)
Black 3,664 (5) 8,400 (5)
Other 2,620 (3) 5,335 (3)
U.S. Census region
Northeast 15,625 (20) 27,621 (17)
Midwest 21,182 (28) 45,920 (28)
South 29,010 (38) 67,905 (41)
West 10,708 (14) 22,694 (14)
Cardiovascular disease
Hypertension 47,208 (62) 95,755 (58)
Acute myocardial infarction 19,479 (26) 55,895 (34)
Congestive heart disease 10,725 (14) 26,183 (16)
Valvular heart disease 7,659 (10) 17,543 (11)
Peripheral vascular disease 7,372 (10) 16,056 (10)
Cardiac arrest or arrhythmia 3,226 (4) 9,054 (6)
Clinical comorbidity
Diabetes 20,689 (27) 41,097 (25)
Chronic pulmonary disease 10,429 (14) 24,871 (15)
Cancer (no metastasis) 5,726 (8) 12,476 (8)
Hypothyroidism 5,844 (8) 12,135 (7)
Fluid or electrolyte disorder 3,293 (4) 8,538 (5)
Renal disease 1,738 (2) 4,257 (3)
Hospitalization in 90 days
before PCI
10,896 (14) 24,561 (15)
Hospitalization in 270 days
before PCI
24,884 (33) 56,051 (34)
Characteristics of PCI hospital
Urban hospital‡ 40,168 (52) 79,762 (49)
Academic hospital§ 21,557 (28) 40,098 (24)
5,000 admissions
per year
12,635 (17) 31,647 (19)
5,000 to 9,999 admissions
per year
35,426 (46) 76,588 (47)
10,000 admissions
per year
28,464 (37) 55,905 (34)
All values given as n (%) unless otherwise indicated. Percentages may not add to 100 because o
n urban county (U.S. Census definition). §Hospital was a member of the American Association of
alendar year, 2002 to 2004
BMS  bare-metal stent(s); DES  drug-eluting stent(s); PCI  percutaneous coronary intervenontrols. In addition, DES patients had lower unadjusted 9nd adjusted rates of the combined outcomes of hospital-
zation for acute myocardial infarction, coronary revascular-
zation, or death compared to both historical and contem-
orary BMS control patients.
ubgroup analyses. We then fitted proportional hazards
urvival models that included age subgroups (ages 66 to 70,
1 to 75, 76 to 80, 81 to 85, and older than 85 years) as well
s race and gender interacted with DES receipt. The only
tatistically significant interaction was for black patients in
he comparison of DES recipients to contemporary BMS
ontrols. The DES hazard ratio for black patients (0.89,
trols*
After Match
andardized
erence (%)†
DES
(n  76,525)
BMS
(n  76,525)
Standardized
Difference (%)†
26 0.81 (0.27) 0.82 (0.27) 1.2
7 75 (6) 75 (6) 0.1
0.6 33,299 (44) 33,472 (44) 0.5
0.6 70,241(92) 70,188 (92) 0.3
2 3,664 (5) 3,734 (5) 0.4
0.6 2,620 (3) 2,603 (3) 0.1
9 15,625 (20) 15,864 (21) 0.8
1 21,182 (28) 21,277 (28) 0.3
7 29,010 (38) 28,705 (38) 0.8
0.5 10,708 (14) 10,679 (14) 0.1
7 47,208 (62) 46,970 (61) 0.6
19 19,479 (26) 20,114 (26) 2
5 10,725 (14) 10,814 (14) 0.3
2 7,659 (10) 7,695 (10) 0.2
1 7,372 (10) 7,348 (10) 0.1
6 3,226 (4) 3,226 (4) 0
5 20,689 (27) 20,813 (27) 0.4
4 10,429 (14) 10,715 (14) 1
0.5 5,726 (8) 5,857 (8) 0.7
0.9 5,844 (8) 5,831 (8) 0.1
4 3,293 (4) 3,412 (5) 0.7
2 1,738 (2) 1,805 (2) 0.6
2 10,896 (14) 11,040 (14) 0.5
3 24,884 (33) 25,022 (33) 0.4
8 40,168 (52) 39,433 (52) 2
9 21,557 (28) 21,246 (28) 1
7 12,635 (17) 12,566 (16) 0.2
0.7 35,426 (46) 35,361 (46) 0.2
7 28,464 (37) 28,598 (37) 0.4
ing. †The difference in means as a percent of the pooled standard deviation. ‡Hospital located in
l College’s Council of Teaching Hospitals and Health Systems. Average Medicare admissions perCon
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May 27, 2008:2017–24 DES Outcomes in the Elderlyp 0.04) from the DES hazard ratio for whites (0.78, 95%
onfidence interval 0.76 to 0.81). None of the other interac-
ions were significant, suggesting the association between DES
nd improved survival was not modulated by age or gender.
iscussion
mong Medicare beneficiaries receiving PCI from mid-
002 to 2003, receipt of a DES was associated not only with
reduction in subsequent coronary revascularization proce-
ures but also with a statistically significant reduction in
atients Receiving DES Compared With Contemporary BMS Contro
Table 2 Patients Receiving DES Compared With Contemporary
Characteristic
Before Match
DES
(n  76,525)
BMS
(n  100,896)
Logit of propensity score (SD) 0.34 (0.43) 0.52 (0.45)
Age, yrs, mean (SD) 75 (6) 75 (6)
Female 33,299 (44) 42,620 (42)
Race
White 70,241 (92) 91,991 (91)
Black 3,664 (5) 5,580 (6)
Other 2,620 (3) 3,325 (3)
U.S. Census region
Northeast 15,625 (20) 15,014 (15)
Midwest 21,182 (28) 29,829 (30)
South 29,010 (38) 42,483 (42)
West 10,708 (14) 13,570 (14)
Cardiovascular disease
Hypertension 47,208 (62) 58,307 (58)
Acute myocardial infarction 19,479 (26) 38,023 (38)
Congestive heart disease 10,725 (14) 17,983 (18)
Valvular heart disease 7,659 (10) 11,103 (11)
Peripheral vascular disease 7,372 (10) 10,143 (10)
Cardiac arrest or arrhythmia 3,226 (4) 6,367 (6)
Clinical comorbidity
Diabetes 20,689 (27) 24,913 (25)
Chronic pulmonary disease 10,429 (14) 16,528 (16)
Cancer (no metastasis) 5,726 (8) 7,659 (8)
Hypothyroidism 5,844 (8) 7,427 (7)
Fluid or electrolyte disorder 3,293 (4) 8,538 (8)
Renal disease 1,738 (2) 2,845 (3)
Hospitalization in 90 days
before PCI
10,896 (14) 14,907 (15)
Hospitalization in 270 days
before PCI
24,884 (33) 33,203 (33)
Characteristics of PCI hospital
Urban hospital‡ 40,168 (52) 46,516 (46)
Academic hospital§ 21,557 (28) 22,226 (22)
5,000 admissions
per year
12,635 (17) 22,993 (23)
5,000 to 9,999 admissions
per year
35,426 (46) 46,617 (46)
10,000 admissions
per year
28,464 (37) 31,286 (31)
All values given as n (%) unless otherwise indicated. Percentages may not add to 100 because o
n urban county (U.S. Census definition). §Hospital was a member of the American Association of
alendar year, 2002 to 2004.
Abbreviations as in Table 1.ortality and fewer hospitalizations for subsequent acute wyocardial infarction. This departure is a striking one from
he results of both individual randomized controlled trials as
ell as pooled analyses from randomized trials, which have
epeatedly demonstrated no statistical differences in survival
r acute myocardial infarction between patients treated with
ES versus BMS.
There are 2 nonexclusive possible explanations for these
ndings. The first is that receipt of DES, particularly “early”
n the DES era (2003), was associated with factors that were
ot observable in our data but which conferred a significant
urvival benefit. This confounder (or set of confounders)
Controls*
After Match
andardized
erence (%)†
DES
(n  71,965)
BMS
(n  71,965)
Standardized
Difference (%)†
41 0.38 (0.41) 0.38 (0.41) 1
11 75 (6) 75 (6) 0.6
3 31,211 (43) 31,186 (43) 0.1
2 65,956 (92) 65,862 (92) 0.5
3 3,580 (5) 3,689 (6) 0.7
0.7 2,420 (3) 2,405 (3) 0.1
15 12,900 (18) 12,860 (18) 0.2
4 20,382 (28) 20,757 (29) 1
9 28,579 (40) 28,281 (39) 0.8
2 10,095 (14) 10,058 (14) 0.2
8 43,909 (61) 43,376 (60) 2
27 19,479 (27) 20,783 (29) 4
10 10,473 (15) 11,030 (15) 2.1
2 7,341 (10) 7,437 (10) 0.4
1 7,105 (10) 7,042 (10) 0.3
9 3,196 (4) 3,365 (5) 1
5 19,163 (27) 18,889 (26) 0.9
8 10,096 (14) 10,609 (15) 2
0.4 5,338 (7) 5,352 (7) 0.1
1 5,448 (8) 5,439 (8) 0.1
8 3,230 (5) 3,550 (5) 2
3 1,688 (2) 1,781 (3) 0.8
2 10,368 (14) 10,400 (15) 0.1
0.8 23,562 (33) 23,337 (33) 0.6
13 36,542 (51) 36,177 (50) 1
14 18,649 (26) 18,936 (26) 1
16 12,633 (18) 12,033 (17) 2
0.2 33,854 (47) 33,483 (47) 1
13 25,469 (35) 26,440 (37) 3
ing. †The difference in means as a percent of the pooled standard deviation. ‡Hospital located in
l College’s Council of Teaching Hospitals and Health Systems. Average Medicare admissions perls*
BMS
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DES Outcomes in the Elderly May 27, 2008:2017–24f mortality and subsequent myocardial infarction that
ould be protective among DES recipients and/or harmful
mong BMS recipients. It is possible that “healthier”
atients (in ways not observable using administrative data)
ere preferentially selected for DES, such as patients with
ess-complex coronary lesions. Patients with DES may have
nadjusted Clinical Outcomes*
Table 3 Unadjusted Clinical Outcomes*
Time After PCI DES BMS p Value
DES patients compared with matched contemporary BMS controls
Mortality
90 days 3.0 4.4 0.001
1 yr 6.5 8.9 0.001
2 yrs 10.7 13.5 0.001
Hospitalization for subsequent AMI
1 yr 7.2 9.3 0.001
2 yrs 9.2 11.2 0.001
Coronary revascularization
1 yr 12.6 14.6 0.001
2 yrs 17.2 19.1 0.001
Combined end points†
1 yr 21.7 26.2 0.001
2 yrs 29.8 34.4 0.001
DES patients compared with matched historical BMS controls
Mortality
90 days 2.9 3.7 0.001
1 yr 6.2 7.9 0.001
2 yrs 10.4 12.2 0.001
Hospitalization for subsequent AMI
1 yr 7.0 9.2 0.001
2 yrs 8.9 11.4 0.001
Coronary revascularization
1 yr 12.6 15.7 0.001
2 yrs 17.3 20.6 0.001
Combined end points†
1 yr 21.4 26.2 0.001
2 yrs 29.5 34.5 0.001
Data are percentages. †Combined end point of mortality, AMI hospitalization, or coronary
evascularization within the specified time period.
AMI  acute myocardial infarction; other abbreviations as in Table 1.
esults of Multivariable Models: Clinical Outcomes*
Table 4 Results of Multivariable Models: Clinical Outcomes*
Time Frame After PCI
DES Compared With Contemporary
Unadjusted
Mortality
N/A (hazard ratio) 0.84 (0.82–0.87) 0
Hospitalization for AMI
1 yr 0.76 (0.73–0.79) 0
2 yrs 0.80 (0.77–0.83) 0
Coronary revascularization
1 yr 0.84 (0.82–0.87) 0
2 yrs 0.88 (0.86–0.91) 0
Combined end points†
1 yr 0.78 (0.76–0.80) 0
2 yrs 0.81 (0.79–0.83) 0Data are odds ratios (95% confidence intervals) unless otherwise indicated. †Combined end point of m
Abbreviations as in Tables 1 and 3.een more likely to have been treated with antiplatelet
gents such as clopidogrel, although clinical guidelines in
003 did not favor clopidogrel use in DES over BMS
ecipients. Patients may have also been selected for DES
ho were more likely to be adherent to medications,
lthough the clinical imperative for patient adherence to
ntiplatelet agents after DES was less apparent in 2003 than
t is currently.
Patients receiving DES also may have had higher quality
ealth care than patients receiving BMS, although if this
ere the case, a marked difference in the comparisons
etween contemporary and historical controls would be
xpected, because historical controls would have included
he same “high-quality” physicians and hospitals that more
apidly adopted DES once this technology was available.
nstead, we found remarkably little difference in the com-
arisons between DES and BMS patients, regardless of the
ontrol group used.
The second possibility is that DES may directly confer a
linical benefit that was not observed by the randomized
linical trials. This may be a function of statistical power:
ach of our analyses included approximately 150,000 pa-
ients, which is nearly 30 times larger than even the largest
ool of clinical trial patients. As such, we had much greater
ower to detect small differences in outcomes. Furthermore,
any clinical trials had very strict entry criteria and an
xtensive array of follow-up activities that may have atten-
ated a difference in clinical efficacy in the trial population.
nother important difference between many of the random-
zed controlled trials and our cohort was the age of the
atients—our cohort’s mean age was 75 years, whereas only
of 14 clinical trials analyzed by Kastrati et al. (17) had
ean ages exceeding 65 years. Our patient population had
greater baseline mortality and adverse clinical event rate
han many of the clinical trial populations, thus potentially
agnifying differences in the effectiveness of treatments. In
act, the observed mortality rate in our cohorts (6% to 9%
er year) was substantially greater than the 1% annual
Controls DES Compared With Historical BMS Controls
usted Unadjusted Adjusted
.81–0.86) 0.79 (0.77–0.81) 0.79 (0.77–0.81)
.73–0.79) 0.74 (0.71–0.76) 0.72 (0.69–0.75)
.78–0.83) 0.77 (0.74–0.79) 0.76 (0.73–0.78)
.81–0.86) 0.78 (0.75–0.80) 0.77 (0.75–0.80)
.85–0.90) 0.81 (0.79–0.83) 0.80 (0.78–0.83)
.77–0.81) 0.77 (0.75–0.79) 0.77 (0.75–0.78)
.80–0.83) 0.80 (0.78–0.81) 0.79 (0.78–0.81)BMS
Adj
.83 (0
.76 (0
.80 (0
.84 (0
.87 (0
.79 (0
.82 (0ortality, AMI hospitalization, or coronary revascularization within the specified time period.
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May 27, 2008:2017–24 DES Outcomes in the Elderlyortality rates observed in the SIRIUS (Sirolimus-Eluting
alloon Expandable Stent in the Treatment of Patients
ith De Novo Native Coronary Artery Lesions) (18),
AVEL (Randomized study with the sirolimus-eluting
ELOCITY balloon-expandable stent in the treatment of
atients with de novo native coronary artery lesions) (19),
nd TAXUS-IV (In-Stent Restenosis Treated With Stent-
ased Delivery of Paclitaxel Incorporated in a Slow-Release
olymer Formulation) (20) trials. It is also possible that the
rocess of coronary restenosis, which has been observed in
linical trial populations as more common among BMS
han DES recipients, was more likely to have adverse
linical consequences such as AMI or death among elderly
atients than among the more robust, younger patients who
ere enrolled in clinical trials.
omparisons with previous investigations. Spaulding et
l. (21) pooled data from 4 clinical trials of sirolimus-eluting
oronary stents versus bare metal stents (n  1,748) and
etermined a 95% confidence interval for the mortality
azard ratio of 0.84 to 1.83. Similarly, Kastrati et al. (17)
xamined mortality among 4,958 patients in 14 randomized
ontrolled trials and calculated a 95% confidence interval
azard ratio for mortality of 0.80 to 1.30. Our point
stimates for mortality hazard ratio (0.79 compared with
istorical controls, 0.83 compared with contemporary con-
rols) are nearly identical to the lower confidence boundary
stimates for both of these studies.
In contrast to our findings, Lagerqvist et al. (22) reported
greater risk of death for DES recipients among 19,771
CI recipients in Sweden from 2003 to 2004, also by using
ropensity score methods to improve adjustment for con-
ounders, but without using matching and subsequent
xclusion of poorly matched patients in the outcomes
nalysis. Use of this technique risks the inclusion of “outlier”
atients who were poorly matched across treatments, thus
ncreasing the potential bias in estimating the effect of DES
23). Our matched analyses excluded patients who were
ssentially unmatchable, thus reducing the potential for
utliers to bias results.
ES Medicare analysis: limitations. This study was
ased on administrative claims data and thus is limited by
he clinical detail such records inherently lack, including
oronary anatomy, results of noninvasive testing, and car-
iac functional status (e.g., echocardiography). Addition-
lly, the Medicare claims we used for this study were solely
erived from fee-for-service patients older than age 66
ears; thus, our results may not apply to younger patients, or
o patients covered by other types of insurance, including
edicare Advantage health maintenance organizations.
Detailed information about adjunctive therapy (including
harmacotherapy) for DES or BMS recipients was unavail-
ble in this analysis of administrative claims data. It is
herefore possible that patients receiving DES were more
ikely to receive other beneficial therapies such as aspirin,
eta-blockers, and cholesterol reducing agents. Further-
ore, recent evidence has suggested that maintenance of Dlopidogrel therapy after PCI may be more essential to
educe late adverse events for DES patients than for BMS
atients. However, data on the importance of extended
lopidogrel therapy for DES patients were not yet available
uring the time-frame of our study, in which all included
atients received stents no later than December, 2003. It is
lso possible that patients with more complex coronary
natomy (e.g., ostial or bifurcation lesions) were selected to
eceive BMS even after DES were available. These lesions
ould have predisposed recipients to worse clinical outcomes,
lthough published data supporting this is inconclusive.
A third limitation to our study is the lack of ideal
omparison groups. Historical controls, even those who
eceived their care with 12 months’ difference in timing,
ay have received different quality health care in other
omains as the result of ongoing enhancements in health
are systems (e.g., quality management programs, electronic
edical records, and so on). Furthermore, the manner in
hich patients were selected for PCI before the approval of
ES may have systematically differed from the selection
rocess once DES were available. Although we believe these
election pressures would have been less pronounced in the
rst 9 months after the new technology became available—
ractice patterns typically change gradually—the possibility
hat a “healthier” cohort of patients was being systematically
elected for PCI after the appearance of DES on the market
annot be excluded. The comparison with contemporary
ontrols may also select for those health systems, hospitals,
nd physicians that were quicker to adopt innovative meth-
ds, and/or that had more resources to invest in new
echnology. Both of these factors could be associated with
mproved survival among patients independent of whether
atients received DES or BMS.
Although propensity score matching can simultaneously
djust for a multitude of factors that systematically differ
etween BMS and DES recipients and that also affect
ealth care outcomes, it would not be effective at controlling
or unmeasured differences (as hypothesized previously) that
ay not be correlated with the measured variables included
n the propensity score model. Our sensitivity analyses
ndicated that the effect of a hypothetical, clinically impor-
ant unmeasured variable would have had to be sizeable, and
ts difference in prevalence among DES and BMS patients
ould need to be extraordinary, to produce the observed
ifference in mortality that we observed between DES and
MS patients. Among the many factors we included in our
ropensity score models, only acute myocardial infarc-
ion—an “off-label” indication for DES—had such a pro-
ounced prevalence difference among DES and BMS re-
ipients before matching. We acknowledge it is not possible
o definitively disprove the existence of a similar, unobserved
onfounder.
mplications. This study has important implications to
olicymakers continuing to face difficult decisions regarding
he value of DES (24). One potential implication is that
ES have previously unrecognized clinical value in reducing
m
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DES Outcomes in the Elderly May 27, 2008:2017–24ortality, although this effect may be confined to, or
ubstantially more pronounced among, elderly patients. A
econd implication, even if there is actually no additional
linical benefit conferred directly by DES, is that there are
ubstantial benefits conferred by hospitals and health care
ystems that adopt new cardiovascular technology more
xpeditiously. As the Centers for Medicare and Medicaid
ervices increasingly scrutinize the performance of hospitals
nd health care systems in terms of quality, an important
arker for better outcomes may be the expeditious use of
ew technologies among clinically appropriate patients.
onclusions
mong elderly Medicare beneficiaries treated with coronary
tents between 2002 and 2003, receipt of DES was associ-
ted with a statically significant reduction in the rate of
ubsequent revascularization procedures, decreasing rates of
ubsequent hospitalization for acute myocardial infarction,
nd improved survival.
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